Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699934 | 0.96 | NCF1 (0.38) | NCF1CHRM2CHRM4CHRM1HRH3 | |
| SCHEMBL1700154 | 0.96 | NCF1 (0.38) | NCF1CHRM2CHRM4CHRM1HRH3 | |
| SCHEMBL1699933 | 0.96 | NCF1 (0.38) | NCF1CHRM2CHRM4CHRM1HRH3 | |
| SCHEMBL6379437 | 0.89 | NCF1 (0.45) | NCF1CHRM2CHRM4CHRM1CHRM5 | |
| SCHEMBL1180398 | 0.87 | NCF1 (0.41) | NCF1CHRM1 | |
| SCHEMBL15045188 | 0.83 | NCF1 (0.32) | NCF1 | |
| SCHEMBL9437303 | 0.82 | NCF1 (0.44) | NCF1 | |
| SCHEMBL1700960 | 0.79 | NCF1 (0.39) | NCF1 | |
| SCHEMBL1700965 | 0.79 | NCF1 (0.39) | NCF1 | |
| SCHEMBL3637358 | 0.79 | NCF1 (0.41) | NCF1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240458-B1 | ARYL SULFONAMIDES AS EFFECTIVE ANALGESICS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110046106-A1 | ARYL SULFONAMIDES AS EFFECTIVE ANALGESICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046106-A1 | ARYL SULFONAMIDES AS EFFECTIVE ANALGESICS | SULT2A1, SULT1A1, ARSA | NCF1 1507/4885CHRM2 476/4885CHRM4 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.